Table 2.
Clinical trial phase | Drug name | Nanoparticle material | Targeting strategy | Target | Disease | Company | Stage |
---|---|---|---|---|---|---|---|
I | Atu027 | Lipid nanoparticle | None | Protein kinase N3 | Solid tumors | Silence Therapeutics | Completed |
I | ALN-VSP | Lipid nanoparticle | None | VEGF and KSP | Solid tumors with liver involvement | Alnylam | Completed |
I | TKM 80301 | Lipid nanoparticle | None | Polo-like kinase 1 | Primary or Secondary liver cancer | NCI | Completed |
I | CALAA-01 | Polymer (cyclodextrin) nanoparticle | Transferrin | RRM2 | Solid tumors | Calando | Terminated |
I | siG12D LODER | Polymer (PLGA) nanoparticle | implanted into tumor | KRASG12D | Pancreatic ductal adenocarcinoma | Silenseed Ltd. | Completed |
I | siRNA-EphA2-DOPC | Lipid nanoparticle | None | EphA2 | Solid tumors | MD Anderson Cancer Ctr | Not yet open |
II | siG12D LODER | Polymer nanoparticle | implanted into tumor | KRASG12D | Pancreatic ductal adenocarcinoma | Silenseed Ltd. | Not yet open |
I | TKM 80301 | Lipid nanoparticle | None | Polo-like kinase 1 | Solid tumors | Tekmira | Recruiting |